Skip to content
DeepViews

Stevanato Group S.p.A. (STVN) — Analysis Summary

Stevanato Group S.p.A. (STVN) has a market cap of $6.09B with year-over-year revenue growth of +12.5%. Net margin stands at 11.8%. The stock trades at a P/E ratio of 38.5.

Key Takeaways

  • Revenue changed +12.5% year-over-year
  • Net margin of 11.8%
  • P/E ratio of 38.5

Compared with its sector, STVN posted revenue growth of +12.5% and trades at a P/E of 38.5.

[XNYS]

Stevanato Group S.p.A. (STVN)

$21.03

UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR

Market Cap
$6090.71M
Enterprise Value
$5937.25M
P/E Ratio
38.5
Div Yield
0.26%
EV/EBITDA
N/A
Company Profile
About
About Stevanato Group S.p.A.

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

Employees

5,795

Exchange

XNYS

Website
Source: Polygon.io
Score
Competitive Moat
Competitive Moat
48
Narrow Moat

Systematic competitive advantage assessment based on 4yr data

This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.

Market Signals
Valuation
Earnings
Insider Activity
Insider Filing Activity

First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.

Loading SEC insider filing activity...
Superinvestors
Financial Health
Financial Health

Capital Structure

Total Equity$1746.67M
Total Debt$0.00M
Debt-to-Equity0.00
Cash & Equivalents$153.46M

Cash Flow

Operating Cash Flow$323.66M
Free Cash Flow$25.25M
FCF Margin1.88%
P/FCF Ratio241.18
Source: Polygon.io · SEC EDGAR
Dividends
Dividends

Annual Dividend/Share

$0.05

Dividend Yield

0.26%

Annual
Last Ex-Date: 2026-06-11

Dividend History

2026-06-11
CD$0.0540
2025-06-05
CD$0.0540
2024-06-04
CD$0.0530
2023-06-07
CD$0.0540
Source: Polygon.io
Recent News
Recent News

Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.